BioPharma Today

Lilly's Cymbalta gets FDA nod for new generalized anxiety disorder indication for maintenance treatment, extending its use beyond the acute treatment setting. 

BIO's Greenwood On India, Bayer's China Strategy, And Pfizer's Lipitor Battle In The Philippines - Latest From PharmAsia News

BIO President Jim Greenwood Says Indian Biosimilars Welcome In U.S. Market: An Interview With PharmAsia News (Part 1 of 2)

11/30/09 8:23 GMT

Latest News From "The Pink Sheet" DAILY

Two-Compound Partnership With Novartis Brings Incyte $210 Million Immediately

The two companies will co-develop an oral JAK1/JAK2 inhibitor in myelofibrosis and likely other indications as well.   read more

Pfizer MOU, Pharmaxis Advisory Cmte. Nod, Otsuka/BMS Withdraw Abilify Extension - Latest From PharmAsia News

Pfizer Signs MOU With Wuhan To Establish First R&D Center In Midwest China; Ranks Number One In China

11/25/09 11:11 GMT

Australia's Pharmaxis Breathing Easier Following U.S. FDA Advisory Committee Recommendation For Bronchial Test Aridol

11/25/09 10:12 GMT

Otsuka, Bristol-Myers Squibb Withdraw Abilify Extension Application In Europe

11/25/09 10:11 GMT

 

Not a subscriber to PharmAsia News? To register for a free trial, click here.

Coming in Monday's "The Pink Sheet" DAILY

In a two-compound partnership, Novartis will pay Incyte $150 million upfront plus an immediate Phase III milestone of $60 million for rights to an oral JAK1/JAK2 inhibitor being investigated in myelofibrosis.

Prevnar 13's Added Strains, Extra Studies Help Insulate Pfizer's U.S. Position

By picking up serotype 19A, Pfizer's next-generation pneumococcal disease vaccine Prevnar 13 is armed to protect against the most prevalent strain of Streptococcus pneumoniae left in the U.S.

The boosted protection in the new vaccine won't likely do much to boost Prevnar 13's commercial viability in the U.S., since the firm's 7-valent Prevnar already dominates the market.  Read on...

Part D Coverage Gap Relief Added To Senate Health Reform Bill; Is It Enough?

The merged Senate health reform bill includes a new provision that would narrow the Medicare Part D coverage gap by $500 in 2010.

Unveiled by Senate leadership Nov. 18, the Patient Protection and Affordable Care Act is a combination of the health reform bills reported out of the Senate Finance Committee and Health, Education, Labor and Pensions Committee.   Read on....

The Asia Corner - From the Editors of PharmAsia News

The Asia Corner - From the Editors of PharmAsia News  November 25, 2009

In this BioPharma Today feature, the editors of PharmAsia News take a closer look each week at the most important biopharma developments from China, India, Japan, and the Pacific Rim.

Read today's features...

Latest News From "The Pink Sheet" DAILY

Clovis Taps Into Rich "A" Round, Grabs Licensing Rights to Improved Gemcitabine

Clovis takes over work on Clavis's pancreatic cancer drug and will develop a companion test to target patients who fare poorly on Lilly's current standard of care.   read more

Coming in Wednesday's "The Pink Sheet" DAILY

Given the shortage of Genzyme’s Cerezyme treatment for Gaucher disease, European regulators decided to grant an accelerated review for Shire’s velaglucerase.